The Seattle-based clinical-stage biopharmaceutical company’s unique drug development environment radically reduces the time and investment required for biologic drug development.

Lumen Bioscience’s patented spirulina technology is designed to enable the manufacturing of biologic drugs at a cost that according to the company is orders of magnitude lower than traditional biotech manufacturing systems—cheap enough even for oral delivery. [Lumen Bioscience]

Lumen Bioscience has made clinical development progress on its lead candidate, LMN-201, an orally delivered biologic cocktail to treat and prevent a form of colitis called C. difficile infection (CDI). Lumen achieved FDA clearance for a planned Phase II study and successfully completed a Phase I first-in-human study, which validated drug delivery of enteric capsules into the gut. LMN-201 combines four therapeutic proteins that work synergistically to neutralize both the C. difficile bacterium and the toxin that causes its virulence . . .

Start Your 30-Day Free Trial Now

Log In Join GEN Edge